Wexford Capital LP Acquires New Holdings in Perspective Therapeutics, Inc. (NYSE:CATX)

Wexford Capital LP bought a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 20,000 shares of the company’s stock, valued at approximately $64,000.

Several other large investors have also recently bought and sold shares of the stock. Two Sigma Advisers LP acquired a new position in Perspective Therapeutics during the 4th quarter valued at about $484,000. Two Sigma Investments LP acquired a new position in Perspective Therapeutics during the 4th quarter valued at about $2,075,000. Sherbrooke Park Advisers LLC acquired a new position in Perspective Therapeutics during the 4th quarter valued at about $69,000. Point72 Asset Management L.P. acquired a new position in Perspective Therapeutics during the 4th quarter valued at about $175,000. Finally, ProShare Advisors LLC increased its stake in Perspective Therapeutics by 49.1% during the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock valued at $49,000 after buying an additional 5,011 shares during the period. Institutional investors and hedge funds own 54.66% of the company’s stock.

Insider Activity at Perspective Therapeutics

In related news, CEO Johan M. Spoor acquired 22,026 shares of the stock in a transaction that occurred on Friday, March 28th. The shares were purchased at an average cost of $2.24 per share, with a total value of $49,338.24. Following the completion of the transaction, the chief executive officer now owns 59,383 shares of the company’s stock, valued at approximately $133,017.92. This trade represents a 58.96% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Robert F. Williamson III acquired 22,192 shares of the stock in a transaction that occurred on Friday, March 28th. The shares were bought at an average cost of $2.27 per share, for a total transaction of $50,375.84. Following the completion of the transaction, the director now directly owns 70,837 shares of the company’s stock, valued at $160,799.99. This represents a 45.62% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 115,696 shares of company stock valued at $256,344. Corporate insiders own 3.72% of the company’s stock.

Analyst Ratings Changes

CATX has been the topic of several research analyst reports. Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research note on Monday, March 31st. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price objective on the stock. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $12.50.

Perspective Therapeutics Trading Up 3.8%

Shares of CATX opened at $2.73 on Tuesday. The company has a 50-day moving average of $2.25 and a two-hundred day moving average of $3.53. Perspective Therapeutics, Inc. has a one year low of $1.60 and a one year high of $16.90.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.